COX-2 INHIBITION IN THE ADJUVANT SETTING FOR COLORECTAL CANCER by Kerr, D

Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. by Kerr, D

Cancer initiatives in developing countries - Introduction by Kerr, D

COLORECTAL CANCER by Kerr, D

Tougher at the top. by Kerr, D

Capecitabine/irinotecan combination regimens in colorectal cancer. by Kerr, D

Clinical development of gene therapy for colorectal cancer. by Kerr, D

Policy: EU data protection regulation-harming cancer research by Kerr, D

Generic drugs: their role in better value cancer care. by Kerr, D

Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment. by Kerr, D

Health policy just got personal. by Kerr, D

NTRAC pioneering a virtual model. by Kerr, D

Capecitabine/irinotecan in coloreetal cancer: European early-phase data and planned trials by Kerr, D

Converting data into currency. by Kerr, D

Novel treatments for hepatocellular cancer. by Kerr, S, Kerr, D

Anthropometric measurement error and the assessment of nutritional status by Ulijaszek, S, Kerr, D

Biological markers: Tailoring treatment and trials to prognosis by Kerr, D, Shi, Y

Can we treat cancer for a dollar a day? Guidelines for low-income countries by Kerr, D, Midgley, R

Capecitabine: have we got the dose right? by Midgley, R, Kerr, D

Adjuvant chemotherapy for stage II colon cancer: less complicated than we thought. by Midgley, R, Kerr, D